Finally, the risk score of patients was calculated in the anti-PDL1 immunotherapy array of advanced urothelial carcinoma (imvigor210 cohort), and the prognosis level of patients was evaluated according to the m-resist criteria. This evidence concerns the gene CD274 and urothelial carcinoma.